GERMANY – Evonik, one of the world’s leading specialty chemical companies based in Germany has announced it is transforming its Health Care division in order to increase customer centricity and market focus.

The company’s operations will be streamlined into three new product lines beginning April 1, 2022: Drug Delivery & Product, Drug Substance, and Health Solutions.

To meet the specific requirements of diverse healthcare markets, each product line builds on core competencies and broad differentiating technology platforms.

The new structure moves the Health Care business line closer to becoming a system solutions partner for the pharmaceutical and biotech industries.

The Health Care business, as part of the Nutrition & Care division, is critical to increasing the division’s share of system solutions from 20% today to more than 50% by 2030.

The Nutrition & Care division’s business is centered on health and quality of life. It creates unique solutions for active pharmaceutical ingredients, medical devices, human and animal nutrition, personal care, cosmetics, and household cleaning.

With approximately 5,300 employees, the division generated sales of €3.56 billion (US$ 3.94 billion) in these resilient end markets in 2021.

This strategic transformation of our business line will unleash innovation and new service potential – for the benefit of our customers and patients. We’re proud to be the preferred development and manufacturing partner for the industry’s most innovative therapies,” said Dr Thomas Riermeier, head of Evonik’s Health Care business line.

The “Drug Delivery & Products” unit, led by Paul Spencer, is dedicated to the advancement of the company’s system solutions for advanced oral and parenteral drug delivery.

This includes a strong portfolio of excipients such as EUDRAGIT and RESOMER, lipids, and lipid nanoparticles (LNPs), as well as CDMO services ranging from feasibility studies to commercial drug products.

Spencer has over 30 years of experience in the pharmaceutical industry, with a focus on drug delivery and biomaterials.

Following this realignment, the company’s custom development and manufacturing organization (CDMO) services for active pharmaceutical ingredients (APIs) and intermediates, as well as its API product portfolio, are now part of the new “Drug Substance” unit.

The Drug Substance unit will be headed by Dr. Stefan Randl, who has over 15 years of experience in the biotech, pharmaceutical, and chemical industries, and specializes in the industrialization of pharmaceutical processes.

He has been leading projects to strengthen Evonik’s position in mRNA and gene therapies since 2020.

Evonik assists customers with scale-up from clinical phases to commercial production, including large-scale high potency APIs (HPAPI) and multi-step complex APIs, based on strong piloting and world-scale facilities in the United States and Germany.

The “Health Solutions” product line, led by Maximillian Yeh, will concentrate on fast-growing markets. The unit combines the businesses of biopharma solutions, medical device solutions, and advanced food ingredients solutions.

Yeh has over 30 years of experience in the chemical and pharmaceutical industries and was previously responsible for the global sales organization of the Health Care business line.

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE